Treatment of chlamydial infections: 2014 Update

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 2, 2015, Pages 205-212

  Kohlhoff, Stephan A ^a   Hammerschlag, Margaret R ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Antibiotics; Chlamydia pneumoniae; Chlamydia trachomatis; Chlamydiae

Indexed keywords

MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; HUMAN; NONHUMAN; RESPIRATORY TRACT INFECTION; REVIEW; CHLAMYDIA INFECTIONS; CHLAMYDIA PNEUMONIAE; CHLAMYDOPHILA INFECTIONS; DRUG EFFECTS; RESPIRATORY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; DRUG RESISTANCE, BACTERIAL; HUMANS; RESPIRATORY TRACT INFECTIONS;

EID: 84921051282     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.999041     Document Type: Review

References (53)

1. Centers for Disease Control and Prevention. 2014 Sexually transmitted diseases treatment guidelines. MMWR 2014;In press
2. Hammerschlag MR, Kohlhoff SA, Darville T. Chlamydia pneumoniae and Chlamydia trachomatis. In: Fratamico PM, Smith JL, Brogden KA, editors. Sequelae and long-term consequences of infectious diseases. American Society for Microbiology, Washington, DC; 2009;p. 27-52
3. Hammerschlag MR, Kohlhoff SA, Gaydos CA. Chlamydia pneumoniae. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 8th edition. Elsevier, Inc., Philadephia, PA; 2014;p. 2174-83
4. Hammerschlag MR, Kohlhoff SA. Treatment of chlamydial infections. Expert Opin Pharmacother 2011;13:542-52
5. Senn L, Hammerschlag MR, Greub G. Therapeutic approaches to Chlamydia infections. Expert Opin Pharmacother 2005;6:1-10
6. Suchland RJ, Geisler WM, Stamm WE. Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob Agents ?Chemother 2002;47:636-42
7. Sandoz KM, Rockey DD. Antibiotic resistance in Chlamydiae. Future Microbiol 2010;5:1427-42
8. Ghuysen JM, Goffin C. Lack of cell wall peptidoglycan versus penicillin sensitivity: new insights into the chlamydial anomaly. Antimicrob Agents Chemother 1999;43:2339-44
9. Jacobsson S, Golparian D, Alm RA, et al. High in-vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea. Antimicrob Agents Chemother 2014;58:5585-8
10. Huband MD, Otterson LG, Doig PC, et al. Benzisoxazoles: in vitro activity of new bacterial DNA gyrase/topoisomerase IV inhibitors against Gram-positive, fastidious Gram-negative, atypical, and anaerobic bacterial isolates. 53rd Annual ICAAC; 10-13 September 2013; Denver, CO, USA. Poster F-1220
11. Kohlhoff SA, Huban MD, Hammerschlag MR. In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother 2014;58:7595-6
12. Chotikanatis K, Kohlhoff SA, Hammerschlag MR. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother 2014;58:1800-1
13. Hammerschlag MR, Roblin PM. The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae. J Antimicrob Chemother 2004;54:281-2
14. Dessus-Babus S, Bébéar CM, Charron A, et al. Sequencing of gyrase and topoisomerase IV quinolones sequence-determining regions of Chlamydia trachomatis and characterization of quinolones resistant mutants obtained in vitro. Antimicrob Agents Chemother 1998;42:2474-81
15. Morrissey I, Salman H, Bakker S, et al. Serial passage of Chlamydia spp. in subinhibitory fluoroquinolone concentrations. J Antimicrob Chemother 2002;49:757-61
16. Kutlin A, Kohlhoff S, Roblin P, et al. Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis. Antimicrob Agents Chemother 2005;49:903-7
17. Batteiger BE, Tu W, Ofner S, et al. Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis 2010;201:42-51
18. Rice RJ, Bhullar V, Mitchell SH, et al. Susceptibilities of Chlamydia trachomatis isolates causing uncomplicated female genital tract infections and pelvic inflammatory disease. Antimicrob Agents Chemother 1995;39:760-2
19. Samra Z, Rosenberg S, Soffer Y, et al. In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. Diagn Microbiol Infect Dis 2001;39:177-9
20. Ljubin-Sternak S, Mestrovic T, Vilibic-Cavlek T, et al. In vitro susceptibility of urogenital Chlamydia trachomatis strains in a country with high azithromycin consumption rate. Folia Microbiol (Praha) 2013;58:361-5
21. Hong KC, Schachter J, Moncada J, et al. Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma. Emerg Infect Dis 2009;15:1088-90
22. West SK, Moncada J, Munoz B, et al. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control. J Infect Dis 2014;210:65-71
23. Seidman JC, Coles CL, Sibergeld EK, et al. Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control. Int J Epidemiol 2014;43(4):1105-13
24. Coles CL, Mabula K, Seidman JC, et al. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae, carriage in young children 6 months after treatment. Clin Infect Dis 2013;56:1519-26
25. Roblin PM, Hammerschlag MR. Microbiologic efficacy of azithromycin and susceptibility to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community acquired pneumonia. Antimicrob Agents Chemother 1998;42:194-6
26. Hammerschlag MR, Roblin PM. Microbiologic efficacy of levofloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrob Agents Chemother 2000;44:1409
27. Hammerschlag MR, Roblin PM. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Int J Antimicrob Agents 2000;15:149-52
28. Roblin PM, Montalban G, Hammerschlag MR. Susceptibility to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob Agents Chemother 1994;38:1588-9
29. Lau C-Y, Qureshi AK. Azithromycin versus doxycycline for genital Chlamydia infections. A meta-analysis of randomized clinical trials. Sex Transm Dis 2002;29:497-502
30. Manhart LE, Gillespie CW, Lowens MS, et al. Standard treatment regimens for nogonococcal urethritis have similar but decline cure rates: a randomized controlled trial. Clin Infect Dis 2013;56:934-42
31. Kong FYS, Tabrizi SN, Law M, et al. Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials. Clin Infect Dis 2014;59:193-205
32. Khosropour CM, Dombrowski JC, Barbee LA, et al. Comparing azithromycin and doxycycline for the treatment of rectal chlamydial infection: a retrospective cohort study. Sex Transm Dis 2014;41:79-85
33. Khosropour CM, Manhart LE, Colombara DV, et al. Sub-optimal adherence to doxycycline and treatment outcomes among men with nongonococcal urethritis: a prospective cohort study. Sex Transm Infect 2014;90:3-7
34. Ito S, Ysuda M, Seike K, et al. Clinical and microbiological outcomes in treatment of men with non-gonococcal urethritis with 100 mg twice-daily dose regimen of sitafloxacin. J Infect Chemother 2012;18:414-18
35. Takahashi S, Hamasuna R, Yasuda M, et al. Clinical efficacy of sitafloxacin 100 mg twice daily for 7 days for patients with non-gonococcal urethritis. J Infect Chemother 2013;19:941-5
36. Miyashita N, Niki Y, Matsushima T. In vitro and in vivo activities of sitafloxacin against Chlamydia spp. Antimicrob Agents Chemother 2001;45:3270-2
37. Roblin PM, Reznik T, Kutlin A, et al. In vitro activity of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657 and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 2003;47:1135-6
38. Geisler WM, Pascual ML, Mathew J, et al. Randomized, double-blind, multicenter safety and efficacy study of rifalazil compared with azithromycin for treatment of uncomplicated genital Chlamydia trachomatis infection in women. Antimicrob Agents Chemother 2014;58:4014-19
39. de Vries HJC, Smelov V, Middleburg JG, et al. Delayed microbial cure of lymphogranuloma venereum proctitis with doxycycline treatment. Clin Infect Dis 2009;48:e53-6
40. Méchaï F, de Barbeyrac D, Aoun O, et al. Doxycycline failure in lymphogranuloma venereum. Sex Transm Infect 2010;86:278-9
41. Oud EV, de Vrieze NH, de Meij A, de Vries HJ. Pitfalls in the diagnosis and management of inquinal lymphogranuloma venereum: important lessons from a case series. Sex Transm Infect 2014;90:279-82
42. Vall-Mayans M, Isaksson J, Caballero E, et al. Bubonic lymphogranuloma venereum with multidrug treatment failure. Int J STD AIDS 2014;25:306-8
43. Nieuwenhuis RF, Ossewaarde JM, van der Meijden WI, et al. Unusual presentation of early lymphogranuloma venereum in an HIV-1 infected patient: effective treatment with 1 g azithromycin. Sex Transm Infect 2003;79:453-5
44. Kurz H, Gopfrich H, Huber K, et al. Spectrum of pathogens if inpatient children and youths with community-acquired pneumonia: a 3 year survey of a community hospital in Vienna, Austria. Wien Klin Wochenschr 2013;125:674-9
45. Conklin L, Adjemian J, Loo J, et al. Investigation of a Chlamydia pneumoniae outbreak in a federal correctional facility in Texas. Clin Infect Dis 2013;57:639-47
46. Capelestagui A, Espana PP, Bilbao A, et al. Poblational Study of Pneumonia (PSoP) Group. Etiology of community-acquired pneumonia in a population-based study: link between etiology and patients characteristics, process of care, clinical evolution and outcomes. BMC Infect Dis 2012;12:134
47. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Disease Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-71
48. Vergis EN, Indorf A, File TM, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients. Arch Intern Med 2000;160:1294-300
49. Pletz MW, Rohde G, Schutte H, et al. CAPNETZ-Studiengruppe. Epidemiology and aetiology of community-acquired pneumonia. Dtsch Med Wochenschr 2011;136:775-80
50. FDA website. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm304177.htm
51. Dzhindzhikhashvili MS, Joks R, Smith-Norowitz T, et al. Doxycycline suppresses Chlamydia pneumoniae-mediated increases in ongoing immunoglobulin E and interleukin-4 responses by peripheral blood mononuclear cells of patients with allergic asthma. J Antimicrob Chemother 2013;68:2363-8
52. Johnston SL, Blasi F, Black PN, et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006;354:1589-600
53. Sutherland ER, King TS, Icitovic N, et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol 2010;126:747-53